PANG Stock Overview
A medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Pangaea Oncology, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.71 |
| 52 Week High | €1.91 |
| 52 Week Low | €1.68 |
| Beta | 0.076 |
| 1 Month Change | -1.72% |
| 3 Month Change | -3.39% |
| 1 Year Change | -2.84% |
| 3 Year Change | -1.16% |
| 5 Year Change | 0.59% |
| Change since IPO | -39.58% |
Recent News & Updates
Shareholder Returns
| PANG | ES Life Sciences | ES Market | |
|---|---|---|---|
| 7D | -4.5% | -4.2% | -2.2% |
| 1Y | -2.8% | -5.3% | 10.7% |
Return vs Industry: PANG exceeded the Spanish Life Sciences industry which returned -3.9% over the past year.
Return vs Market: PANG underperformed the Spanish Market which returned 12.3% over the past year.
Price Volatility
| PANG volatility | |
|---|---|
| PANG Average Weekly Movement | 2.4% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in ES Market | 5.7% |
| 10% least volatile stocks in ES Market | 0.6% |
Stable Share Price: PANG has not had significant price volatility in the past 3 months compared to the Spanish market.
Volatility Over Time: PANG's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 159 | Javier Rivela-Rodriguez | www.panoncology.com |
Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, such as mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation, validation against commercially available platforms, and Ad-hoc R+D for diagnostics companies. It also provides biomarker discovery to identify novel targets for targeted therapies in pre-clinical development.
Pangaea Oncology, S.A. Fundamentals Summary
| PANG fundamental statistics | |
|---|---|
| Market cap | €58.75m |
| Earnings (TTM) | -€5.32m |
| Revenue (TTM) | €14.35m |
4.1x
P/S Ratio-11.1x
P/E RatioIs PANG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PANG income statement (TTM) | |
|---|---|
| Revenue | €14.35m |
| Cost of Revenue | €2.58m |
| Gross Profit | €11.77m |
| Other Expenses | €17.09m |
| Earnings | -€5.32m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 82.01% |
| Net Profit Margin | -37.03% |
| Debt/Equity Ratio | 23.0% |
How did PANG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 11:50 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pangaea Oncology, S.A. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luis Esteban Arribas | Lighthouse-IEAF Servicios de Analisis |